WO1995033205A1 - Procede et dispositif simplifie de dosage immunochimique - Google Patents

Procede et dispositif simplifie de dosage immunochimique Download PDF

Info

Publication number
WO1995033205A1
WO1995033205A1 PCT/JP1995/001006 JP9501006W WO9533205A1 WO 1995033205 A1 WO1995033205 A1 WO 1995033205A1 JP 9501006 W JP9501006 W JP 9501006W WO 9533205 A1 WO9533205 A1 WO 9533205A1
Authority
WO
WIPO (PCT)
Prior art keywords
labeling substance
analyte
sample
quantitative
substance
Prior art date
Application number
PCT/JP1995/001006
Other languages
English (en)
Japanese (ja)
Inventor
Hideaki Manita
Kenichi Tajima
Original Assignee
Teikoku Hormone Mfg. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP11512294A external-priority patent/JP3552272B2/ja
Priority claimed from JP11691394A external-priority patent/JP3519451B2/ja
Application filed by Teikoku Hormone Mfg. Co., Ltd. filed Critical Teikoku Hormone Mfg. Co., Ltd.
Priority to AU25378/95A priority Critical patent/AU2537895A/en
Publication of WO1995033205A1 publication Critical patent/WO1995033205A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow

Definitions

  • the present invention relates to a simple immunochemical assay method and apparatus capable of easily and qualitatively or quantitatively (semi-quantitatively) clarifying and quantifying (semi-quantitatively) a sample containing an analyte in a short time.
  • immunological measurement methods are widely used due to their high sensitivity.
  • the so-called immunochromatography method using chromatography is easy to operate and requires only a short time for testing, so it is widely used in many situations today, such as clinical tests in hospitals and testing tests in laboratories. It is used.
  • the most common method of detecting a target substance in the immunochromatography method is to react a specific binding substance with various labels on a substance to be detected on a chromatographic material, and to detect a substance to be detected and a labeled specific binding substance.
  • Antigen-antibody complex is formed and confirmed (detected) by various means.
  • Labels include radioisotopes, chromophores, fluorophores, enzymes, colored particles, and the like.
  • Examples of the detection means include a method using equipment such as a radiation detector and a spectrophotometer, and a method of visually confirming.
  • the qualitative analyzer based on the immunochromatography method is generally based on the immunochemical San Germanti method and the competitive method.
  • the configuration of the device is generally based on the site to which the sample containing the analyte is added (sample addition section) and the analyte.
  • Sites containing labeling substances that serve as indices for detection (labeled sites), sites that capture and detect analytes (detection sites) And a part (absorber) that absorbs and removes excess sample.
  • the sample containing the substance to be detected is appropriately diluted, a qualitative reaction is performed with a measurement reagent having a certain sensitivity, and the highest dilution ratio that indicates positive is determined.
  • the semiquantitative value was calculated by multiplying the sensitivity, or a qualitative reaction was performed using reagents with different measurement sensitivities without diluting the sample, and the semiquantitative value was determined based on the sensitivity of the positive reagent.
  • Methods for quantitative analysis include liquid-phase assays performed in containers such as test tubes and microtiter tubes, and solid-phase assays performed on chromatographic media.
  • a unit type for example, Japanese Patent Application Laid-Open No. Hei 4-351926, International Publication No. WO94 / 28415 by the present applicant
  • a sample addition part on one attrib A so-called stick type consisting of a part where a labeled substance is present, a plurality of detectors with different concentrations (sensitivities) of analytes (sensitivity) that can be detected, and an absorber (see, for example, JP-A-5-57) 4 No. 3).
  • the analyte added to the sample addition section is a specific substance which is not immobilized on the chromatographic material at a predetermined amount (concentration) and a specific substance present on the chromatographic material at a predetermined amount.
  • a certain amount of the analyte binds to the specific substance, but if the analyte is present in excess of the specific substance, the specific binding substance (specific substance or ⁇ The part where the target substance can bind to the same binding site as the specific substance) is immobilized on the chromatographic material
  • Detection unit In the detection section, there is no site capable of binding to the specific substance, and at least the analyte bound to the specific substance passes through the detection section. At least only the analyte-labeled specific binding substance conjugate having a site capable of binding to the specific substance is immobilized in the detection section, and the immobilized conjugate is detected by various detection means. is there.
  • each strip is treated with an antibody against the analyte that is immobilized in a stepwise different amount on each strip before the qualitative analysis of the analyte.
  • the apparatus described in Clinical Chemistry uses lipoprotein (a), a complete antigen, as an analyte, and relates to a competition method using colloidal selenium-labeled lipoprotein (a).
  • the device used has multiple measurement areas (detectors) on a single assay strip, and the most upstream detector has an anti-lipoprotein (a) that is immobilized on the downstream detector. The same amount of antibody is immobilized on all other downstream detection sections, with the same amount of antibody immobilized as the antibody.
  • JP-A-5-57443 discloses an immunoassay apparatus comprising a filter, a labeling reagent-containing member, and a porous carrier having one or a plurality of reaction regions, wherein the porous carrier is located upstream thereof.
  • the filter is sandwiched between the filter and the labeling reagent-containing member, the reaction region is located downstream of the filter and the labeling reagent-containing member, and the labeling reagent-containing member contains the labeled reagent.
  • a measurement device for measuring an analyte using a specific reaction wherein a capture reagent is fixed in a reaction region. By immobilizing more capture reagents as the reaction area is located downstream, semi-quantitative analysis can be performed.
  • the sample addition section (sample application section) of the measurement device described in this publication has a labeling reagent-containing member arranged below the upstream end of the chromatographic material (porous carrier) as shown in c) of Fig. And a filter is arranged in the filter.
  • a labeling reagent-containing member arranged below the upstream end of the chromatographic material (porous carrier) as shown in c) of Fig.
  • a filter is arranged in the filter.
  • the elution of the labeling substance from the site where the labeling substance exists may be slower than the flow rate of the added sample to the chromatographic material. Since the labeling substance does not move on the chromatographic material in synchronization, the pattern tends to be unclear when detecting the analyte. That is, the sample is analyzed Even after passing through the detection site of the target object, the labeling substance gradually elutes and moves to the detection site, so that the coloration at the detection unit becomes stronger over time, or the other than the detection unit on the chromatographic material Light color may be seen in some parts. These phenomena often make qualitative or quantitative (semi-quantitative) results uncertain.
  • the present invention provides an assay by the immunochromatography method, in which a sample containing an analyte and a labeling substance for detecting the analyte are synchronously moved on a chromatographic material to obtain a clear and reliable assay result in a short time.
  • the primary purpose is to provide a means for carrying out such tasks.
  • Japanese Patent Application Laid-Open No. 5-57434 discloses a semi-quantitative device in the form of a stick.
  • this method mainly uses a complete antigen or an antibody against it as an analyte, and a hapten as an analyte.
  • the method described in this publication has room for improvement in the clarity of analysis results (chromatographic patterns).
  • the present invention provides a simpler, faster and more reliable (clear) determination result, and a semi-assay method using a stick-type immunochromatography method comprising a single assay strip capable of performing semi-quantitative determination of hapten with a small sample amount.
  • a second object of the present invention is to provide a method for quantification, which can also achieve the first object of the present invention.
  • a third and fourth object of the present invention is to provide an assay device having a configuration capable of achieving the first and second objects. Disclosure of the invention
  • the first object of the present invention is an immunochemical qualitative or quantitative (semi-quantitative) analysis by a chromatographic method, wherein a labeled substance serving as an index for determination is dissolved by a sample containing an analyte and the analyte is analyzed. Where the substance and the labeling substance read the judgment result on the chromatographic material In the Atsey method, including moving to the head (C)) and visually determining the analysis results;
  • the second object of the present invention is that, when a hapten is an analyte, the composition of the invention I further comprises (1) a hapten as an analyte in a sample, and (2) a labeled analyte. (3) Antibodies to the analyte immobilized on the same chromatographic material and the upstream of the chromatographic material at different concentrations at different concentrations from upstream to downstream.
  • a simple immunochemical assay method characterized in that an antigen-antibody reaction is performed in a competitive manner sequentially from the downstream to the downstream, and the concentration of the analyte in the sample is determined using the label as an index.
  • invention II this method is sometimes referred to as “invention II”.
  • the third object of the present invention is to provide a sample addition section (A) for adding a sample containing an analyte, a specific binding substance to a labeled analyte, or a labeled analyte or a chemical thereof.
  • A sample addition section
  • B where the target denatured substance (labeled substance) is capable of chromatographic transfer, and one or more detectors
  • C detectors
  • the labeling substance-containing member (b) constituting the labeling substance existing part (B) is laminated with the labeling substance elution accelerating member (i) made of a material having an eye roughness equal to or greater than that of the labeling substance-containing member (b). And a member (a) constituting the sample addition section (A) is brought into contact with the labeling substance elution accelerating member (i).
  • invention III the fourth object of the present invention is the above-described invention III, further comprising the step of: Device having a plurality of detectors (C on a single assay strip)
  • FIG. 1 is a diagram showing a basic configuration of a semi-quantitative device (Invention III) having a configuration of a labeling substance existing portion (B) of the present invention.
  • FIG. 2 is a diagram showing the configuration of the device of the present invention (Invention IV) for the purpose of semi-quantitative determination of hapten.
  • FIG. 3 is an enlarged view of a labeled substance present portion (B) which is a characteristic portion of the present invention.
  • FIG. 4 is a diagram showing a configuration of a labeling substance existing portion (B) of a conventional semi-quantitative device.
  • the reference numerals in the figure indicate the following.
  • Inventions I to IV are roughly classified into complete antigens and haptens (incomplete antigens).
  • the complete antigen refers to an antigenic substance capable of inducing antibody production by itself (immunogenicity), and mainly includes peptide hormones having a large molecular weight.
  • Haptens (incomplete antigens) are those that can bind to an antibody but do not have the ability to induce antibody production by themselves, such as peptides with relatively small molecular weight (molecular weight of about 1000 or less). included.
  • the hapten obtains an antibody-producing ability when bound to a suitable carrier, for example, a protein such as serum albumin. Specific examples of these are shown below, but are not limited to those described here.
  • GH Growth hormone
  • ACTH adrenocorticotropic hormone
  • MSH melamine cell stimulating hormone
  • TSH thyroid stimulating hormone
  • LH luteinizing hormone
  • FSH follicle stimulating hormone
  • Gastrointestinal hormones such as gastrin and secretin
  • Placental hormones such as human placental gonadotropin (hCG) and human placental lactating hormone (hPL)
  • Enzymes such as prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), alkaline phosphatase, transaminase, lactate dehydrogenase (LDH), transaminases, trypsin, and pebcinogen.
  • AFP human phytoprotein
  • CEA carcinoembryonic antigen
  • Serum protein components such as immunoglobulin G (IgG), fibrin-fibrinogen degradation products (FDP, D-dimer), antithrombin II (ATIII), transferrin, etc.
  • Substances such as rheumatoid factor, serotonin, perokinase, ferritin, substance P, etc.
  • haptens incomplete antigens
  • Estrogen such as estrone, estradiol, estriol, estetrol, equilin, equilenin
  • Corticosteroids such as cortisol, cortisone, deoxycorticosterone, aldosterone, and tetrahydrocortisol
  • Bile acids such as vitamin D, cholesterol, cholic acid, deoxycholic acid and kenocholic acid, and other steroids such as cardiotonic steroids, saponins and sapogenins
  • Morphine codin, heroin, morphine hydrochloride, cocaine, mescaline, nopaverine, narcotine, yohimbine, reserpine, ergo-yumin, strikinine, etc.
  • Non-antigenic low-molecular peptides such as TRH and LH-RH
  • Thyroid hormones such as jodothyronine, triothyronine, and thyroxine
  • Prostaglandin E2 Prostaglandin: E3
  • Prostaglandin F1 Prostaglandins such as
  • Vitamin A B vitamins (vitamin B1, B2, B6, B12, etc.), vitamin E.
  • Antibiotics such as penicillin, actinomycin, chloromycetin, tetracycline, etc.
  • a sample is not limited as long as it contains the above-mentioned analyte, and mainly includes biological samples such as urine, serum, plasma, blood, saliva, amniotic fluid and the like.
  • the label that serves as an indicator of the qualitative or quantitative analysis of the analyte may be either a direct label or an indirect label.
  • Direct labeling is preferred because it allows the assay results to be visually observed and does not require additional processing or steps.
  • indirect signs a process, process or device is required to visualize the sign after the completion of the atssay.
  • Labels that can be used for direct labeling include metal sols, colored latex particles, color indicators, coloring substances contained in ribosomes, dyes such as various dyes and pigments, and non-metallic sols such as carbon sol. , Luminol derivatives, chemiluminescent substances such as acridinium ester, and fluorescent substances such as fluorescein and rhodamine, but are not limited thereto.
  • Labeled substances that can be used for indirect labeling include, but are not limited to, various enzymes such as peroxidase, 3-galactosidase, alkaline phosphatase, perease, and glucose oxidase.
  • direct labeling it can be obtained by visual observation of color tone, color density, luminescence intensity, fluorescence intensity, etc.
  • indirect labeling it can be obtained by changing the enzyme's substrate or chromogen depending on the enzyme used Detection is performed by measuring color density, luminescence intensity, etc.
  • Labeling substance in the present invention is a substance bound with the labeling, the type of analyte (or antigen or antibody, fully antigen or hapten or the like) different c by, for example, the principle of the measurement method, the analyte is completely If it is an antigen and the measurement principle is the immunological sandwich method, the labeling substance is a substance that binds the above-mentioned labeling substance to a specific binding substance (for example, an antibody) for the analyte, and the analyte is a hapten (measurement The principle is a competitive method), for example, those in which the above-mentioned label is bound to the analyte hapten or a chemically modified product thereof.
  • the chemically modified hapten is a chemical modification of the analyte hapten, which can competitively bind to an antibody against the analyte hubten in the presence of the analyte hapten.
  • Hapten is a substance that is chemically modified. The chemically modified hapten and its modification method will be described later.
  • the hapten which is a component of the labeling substance may be the hapten itself which is the analyte or the hapten which can bind to the detection antibody by a cross-reaction with the hapten which is the analyte. Good.
  • the labeling substance-containing member (b) of the present invention refers to a member in which the labeling substance is retained in a state where it can be chromatographed, and the retained labeling substance is dissolved by a sample solution containing the analyte and labeled. Move from the substance-containing member (b) to the chromatographic material, and move to the site (detection section (C)) where the qualitative or quantitative results are read together with the analyte.
  • the labeling substance-containing member (b) is the same as the chromatographic material in which the detection section (C) is present, that is, the labeling substance-containing portion may be present on the chromatographic material, or may be a member different from the chromatographic material. However, it is preferable to use a member different from the chromatographic material. This is because the effect of the labeling substance elution accelerating member (i) described below can be more exerted.
  • the labeling substance elution accelerating member (i) refers to the labeling substance-containing member (b) that forms the labeling substance-presenting part by the capillary action of the sample solution containing the analyte added to the sample adding part.
  • speeding up the labeling substance to a state where it can be chromatographed, and synchronizing the analyte with the labeling substance is made of the same material as the labeling substance-containing member (b) or a coarser material.
  • the labeling substance elution accelerating member (i) is a standard that indicates the coarseness of the filter media.
  • a material of 10 / m or more is preferable, and a material of 30 to 5 is more preferable.
  • a material having an average flow pore diameter in the above range glass fiber, woven fabric, non-woven fabric, or the like is preferable, and porosisilicate glass fiber is particularly preferable.
  • the material of the labeling substance elution promoting member (i) it is necessary to use a material having an average flow hole diameter equal to or larger than that of the labeling substance-containing member (b) (coarse). The reason for this is that the sample penetrates uniformly and quickly into the laminated labeling substance elution promoting member (i), and the “labeling substance elution promoting member (i)” ⁇ “labeling substance containing member (b)” ⁇ It is considered that the flow of “chromatographic material” is promoted, and the labeling substance is redissolved from the labeling substance-containing member (b) —the chromatographic transfer is accelerated.
  • the labeling substance containing member (b) is made of glass fiber
  • the labeling substance elution promoting member (i) is made of cellulose filter paper or Glass fiber filter paper is preferred.
  • the labeling substance-containing member (b) and the labeling substance elution accelerating member (i) may be made of the same material.
  • both are preferably made of glass fiber, woven fabric or nonwoven fabric, and both are boroboro.
  • the silicate is glass fiber.
  • dissolution in the case where “the labeling substance is dissolved” means that when the labeling substance is wetted by the sample, the labeling substance is in a state capable of chromatographic transfer.
  • the semi-quantitative method for hapten of Invention II is based on an immunochemical competitive reaction. That is, the analyte hapten in the sample and the labeling substance competitively bind to the specific binding substance (preferably an antibody) for the analyte immobilized in the detection section (C). Take advantage of that. Then, a plurality of detection units ( ⁇ !
  • ⁇ ⁇ composed of antibodies immobilized and present on the same chromatographic material are provided independently in order from upstream to downstream at a plurality of different concentrations, and each of these plurality of detection units (( ⁇ ⁇ ⁇ ) In the detection section (C), the hapten of the analyte in the sample and the labeled substance are subjected to antigen-antibody reaction in a competitive manner, and the coloring of the labeled substance appears according to the concentration of the analyte. Analyte concentration based on the number of
  • the concentration of the analyte and the number of the detection units (C) detected (confirmed) by the label are inversely proportional. In other words, the higher the analyte concentration, the smaller the number of detectors (C) to be detected (confirmed).
  • an antibody against the analyte hapten (hereinafter referred to as a hapten antibody) is immobilized as a detection substance on the detection section (C), and the hapten-carrier protein labeled as a labeling substance is bound on the labeling substance existing section (B).
  • a carboxyl group-containing high molecular weight compound having a carboxyl group (hereinafter referred to as a labeled hapten-carrier conjugate) which is chemically bound to a product or a hapten or a chemically modified product thereof.
  • the sample solution causes the label-hapten-carrier conjugate present in the labeling substance existing section (B) to elute and become ready for chromatographic transfer.
  • the label Haputen one carrier conjugate and analysis object moves the detection unit by chromatography moved to (C), successively a plurality of detecting portions (C i ⁇ C n) hapten antibodies present in different immobilized amount competing To combine.
  • the minimum concentration (detection sensitivity) of the analyte which is capable of competitively inhibiting the binding reaction between the two, can be determined by the amount of the hapten antibody and the amount of the label-habten-carrier conjugate. Therefore, if different amounts of hapten antibodies are immobilized on multiple detectors (C to Cn) on the same chromatographic material, quantitative analysis with multiple levels of detection sensitivity can be performed on one chromatographic material. It can be done in one operation. How to set the detection sensitivity, that is, the range of the concentration (fixed amount) of the hapten antibody to be immobilized, should be appropriately selected depending on the analyte, the sample containing it, and the like.
  • the concentration may be sequentially increased from upstream to downstream, or may be sequentially decreased, but the concentration may be sequentially increased from upstream to downstream. It is more preferable to comb. The reason for this is that the competition reaction occurs sequentially from the immobilized low-concentration hapten antibody upstream, so that the detection sensitivity can be increased and the detection concentration range can be narrowed.
  • the hapten antibodies used in the present invention may be conventional antibodies (polyclonal antibodies) or monoclonal antibodies, and can be prepared by a known method.
  • the hapten (analyte) or its chemically denatured product is bound to a substance having antigenicity such as serum serum albumin (BSA), and an antiserum is obtained by immunizing animals according to a conventional method using this as an antigen. Then, antibodies that are reactive only with the hapten (analyte) are separated from the obtained antiserum.
  • BSA serum serum albumin
  • spleen cells of a mouse immunized with the above antigen and myeloma cells are fused, and a fused cell producing the desired antibody is selected to obtain a monoclonal antibody produced from the fused cell.
  • hapten or a chemically modified product thereof which is a component of a water-soluble monoolefin polymer containing a carboxyl group and a hapten-carrier protein-conjugated product or a hapten or a chemically modified product thereof chemically bonded thereto, are not competitive.
  • Carrier protein or carboxyl group-containing water-soluble monoolefin polymer provides a binding site for a label or a chromatographic material to increase the reactivity with the corresponding hapten antibody. It fulfills.
  • Serum-derived proteins and ovalbumin such as rabbit serum albumin (BSA), rabbit serum albumin (RSA), goat serum albumin (GSA), and human serum albumin (HSA), are used as carrier proteins. be able to. When these are used, these proteins (for example, BSA) are used for the purpose of imparting antigenicity to haptens when producing hapten antibodies, and therefore, they have binding properties to these proteins. It is necessary to completely absorb and remove the antibody.
  • BSA rabbit serum albumin
  • RSA rabbit serum albumin
  • GSA goat serum albumin
  • HSA human serum albumin
  • Chemical modification of the hapten is performed by chemically modifying the hapten so that it can chemically bond to the functional group of the water-soluble monoolefin polymer compound containing a carboxyl group (hereinafter referred to as spacer), for example, a carboxyl group or a hydroxyl group. Is added.
  • Chemical modification can be performed by a known method according to the chemical structure of the hapten to be used. In particular, chemical modification to introduce carboxyl, amino and hydroxyl groups into hapten The method is preferred.
  • the spacer used in the present invention is a substance which is physiologically inert and generally does not have antigenicity.
  • the spacer may have a hydroxyl group in addition to the carboxyl group, and these functional groups not only participate in the chemical bond with the hapten or its chemically modified product, but also in the polymer compound. It has the role of imparting water solubility to a certain spacer.
  • “water-soluble” of the spacer water-soluble monoolefin polymer containing a carboxyl group means that at least 1 part by weight of the spacer is completely dissolved in 1000 parts by weight of distilled water. To form a clear solution.
  • Spacer - average molecular weight of may be about 1 o 3 ⁇ 1 0 7 or more, it is usually preferable of about several tens of thousand to several million.
  • the spacer include, for example, a home or copolymer of acrylic acid or methacrylic acid; a copolymer of maleic acid and vinyl acetate or a saponified product thereof; maleic acid and vinyl alcohol, for example, lower alkyl vinyl ether; And acrylic acid or a lower alkyl ester thereof, a copolymer with methacrylic acid or a lower alkyl ester thereof, or a hydrolyzate thereof.
  • a home or copolymer of acrylic acid or methacrylic acid a copolymer of maleic acid and vinyl acetate or a saponified product thereof
  • maleic acid and vinyl alcohol for example, lower alkyl vinyl ether
  • acrylic acid or a lower alkyl ester thereof, a copolymer with methacrylic acid or a lower alkyl ester thereof, or a hydrolyzate thereof for example, a home or copolymer of acrylic acid or methacrylic acid
  • a copolymer is, for example, a copolymer of acrylic acid or methacrylic acid and, for example, /?-Hydroxyethyl ester of acrylic acid or acrylamide, or a terpolymer having the above monomer as a structural unit. There may be.
  • the chemical bond between the hapten or its chemically modified product and the spacer is formed by an amide bond or an ester bond, and particularly preferably by an amide bond.
  • an amide bond for example, a known carpoimide method, a carbonyldiimidazole method, a mixed acid anhydride method, an active ester method, an azide method, an acid chloride method, and a diphenylphosphoryl azide (DPPA) method And carbodiimide method or DPPA method.
  • DPPA diphenylphosphoryl azide
  • the formation of the ester bond may be the case where the reactive hydroxyl group of the hapten or its chemically modified product is bonded to the carboxyl group of the spacer, and vice versa.
  • the carboxyl group of the spacer is converted into a reactive derivative, for example, an acid chloride.
  • the reaction may be carried out with the hydroxyl group of the pentene, or with the hapten as it is if the spacer is a copolymer containing, for example, maleic anhydride.
  • the principle of the method of forming an ester bond is the same as the former, but some haptens may not be stable enough to convert the carboxyl group into a reactive derivative, for example, an acid chloride.
  • FIG. 1 The device shown in a) of FIG. 1 is a basic example of the device of the present invention.
  • the apparatus of the present invention is a chromatographic type immunochemical qualitative or quantitative apparatus including a sample addition section (A;), a labeling substance existing section (B), a detection section (C), and an absorption section (D).
  • the labeling substance elution promoting member (i) is laminated on the labeling substance-containing member (b) constituting the substance existing part (B), and the sample addition section (A) is further formed on the labeling substance elution promoting member (i).
  • the members (a) to be formed are brought into contact with each other.
  • the device of the present invention (Invention I) is characterized by a specific configuration of the labeling substance existing portion (B), and the other portions and the portions added in addition to the above-described configuration of the present invention are particularly limited. There is no.
  • the site other than the characteristic portion of the present invention or the site to be added differs depending on whether it is qualitative analysis or quantitative analysis, and the configuration corresponding to the analyte should be appropriately selected.
  • the device of the present invention can be applied to a so-called stick type or unit type as shown in FIG. 1 for quantitative (semi-quantitative) analysis, but the stick type device is more suitable for the present invention. The effect of is directly exhibited.
  • the apparatus of the present invention uses a sample addition section (A), a labeled substance presence section (B), a plurality of detection sections (( ⁇ to ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ) and a stick type chromato-immunochemical analyzer sequentially having an absorption section (D).
  • the device of the present invention shown in FIG. 2 is generally manufactured as follows. That is, attaching the double-sided adhesive tape (f) a support (e), to expose the adhesive portion and f 2. Place the upstream end of the chromatographic material (g) containing multiple detectors (C! To Cn) with an appropriate overlap on the adhesive, and fix it.
  • the labeling substance elution promoting member (i) is placed on the upstream end side of the labeling substance-containing member (b) with an appropriate overlap, and the sample addition section is placed thereon.
  • the material of the support (e) is plastic, glass, film, or the like, and should be appropriately selected depending on the type of the sample, the type of the analyte, and the like.
  • the shape of the support (e) is preferably a rectangle with a length of 3 to 10 cm and a width of 0.5 to 2 cm. However, it depends on the type of the object to be analyzed, the number of detectors (C) set, the time of assembly, etc. It should be changed as appropriate.
  • the double-sided pressure-sensitive adhesive tape (f) is not particularly limited as long as it does not inhibit chromatosis, and commercially available tapes can be used.
  • the method of connecting the members constituting (A) to (D) is not particularly limited, and is not limited to an adhesive tape, and may be any method that can be connected.
  • the characteristic portion is the configuration of the labeling substance existing portion (B), and the other basic configuration is as described with reference to FIGS. 1 and 2 above.
  • Fig. 3 shows an enlarged view of the labeled substance present area (B).
  • Examples of the material of the member (a) constituting the sample addition section include those having uniform characteristics such as cellulose filter paper, glass fiber, polyurethane, polyacetate, cellulose acetate, nylon, and cotton cloth, but are not limited thereto. Not something.
  • the sample addition section not only receives the sample containing the added analyte, but also has the function of filtering insoluble matter particles in the sample, etc., and therefore has a filtering function such as cellulose filter paper and glass fiber filter paper. Are preferred.
  • the material constituting the sample addition part must be prepared in advance. It is particularly preferable to use it after a non-specific adsorption prevention treatment.
  • the non-specific adsorption prevention treatment include a treatment with an inactive protein, a treatment with a surfactant, and the like.
  • the treatment with an inactive protein is performed, for example, using a material of 0.1 to 10% bovine serum albumin (BSA) 0.1M Tris buffer (pH 6 to 9) solution, 0.1 to 1 °% skim milk 0.
  • BSA bovine serum albumin
  • Tris buffer pH 6 to 9
  • the treatment with a surfactant comprises, for example, immersing the material in a 0.01% to 1% solution of Tween 20 or Triton X100, which is a nonionic surfactant, and drying it.
  • Tween 20 or Triton X100 which is a nonionic surfactant, and drying it.
  • the labeling substance existing part (B), which is a characteristic part of the present invention, comprises a labeling substance-containing member (b) and a labeling substance elution promoting member (i).
  • the material of the labeling substance elution promoting member (i) is as described above, and the treatment for preventing the analyte and the labeling substance from non-specifically adsorbing to the material constituting the labeling substance elution promoting member (i) is performed. After drying, make it.
  • the material constituting the labeling substance-containing member (b) used in the present invention can be the same as or different from the labeling substance elution promoting member (i) described above.
  • Examples of the raw material include cellulose filter paper and Examples thereof include glass fiber filter paper, nonwoven fabric, and glass fiber.
  • Preferred combinations of the components of the labeling substance-containing member (b) and the labeling substance elution promoting member (i) are as described above.
  • the labeling substance-containing member (b) is prepared by treating the analyte and the labeling substance to prevent non-specific adsorption, then impregnating a certain amount of the labeling substance and drying.
  • the labeling substance-containing member (b) may be located on the same chromatographic material (g) as the detection unit (C), or it may be independent and different. It may be made of a material.
  • the labeling substance-containing member (b) When the labeling substance-containing member (b) is located on the same chromatographic material (g) as the detection unit (C) described below, the detection substance is immobilized on the chromatographic material (g), and the analyte, the After the non-specific adsorption prevention treatment, apply the labeling substance to the upstream of the detection part (C) of the chromatographic material (g) and dry.
  • the labeling substance-containing member (b) is made of a material different from the chromatographic material (g) in which the detection unit (C) described below is located, non-specific materials such as glass fiber, cellulose filter paper, glass fiber filter paper, and nonwoven fabric After the anti-adsorption treatment, a certain amount of labeling substance is impregnated and dried.
  • the labeling substance chromatographic material (g) the application or impregnation to the labeling substance-containing member (b) is preferably performed in the presence of a saccharide such as 0.1 to 10% mannitol or 0.1 to 30% saccharose.
  • invention IV The most important factor in accurately performing the semi-quantitative determination of hawthorn with the apparatus of the present invention is that the analyte and the labeling substance in the sample are chromatographically moved in synchronization with each other, and both are detected by each detection unit ( (It is to arrive at ⁇ ⁇ (: ⁇ ) at the same time and perform a competitive reaction. That is, the elution of the labeling substance from the labeling substance existing part (B) is slow, and only the analyte is detected first. After reaching the part and reacting with the detection substance, the labeling substance is
  • the analyte hapten and the labeling substance which are the measurement principles of the present invention, undergo incomplete competition reaction with the detection substance, and the result of the assay becomes uncertain.
  • the structure of the labeling substance existing portion (B) is configured such that the labeling substance elution promoting member (i) is laminated on the labeling substance-containing member (b).
  • the detection section (C) is usually prepared by immobilizing a substance for detection on a part of the chromatographic material (g).
  • the method of immobilizing the substance for detection includes a method in which the substance for detection is directly immobilized on a part of the chromatographic material (g) by physical or chemical bonding, and a method in which the substance for detection is physically or There is an indirect immobilization method in which the fine particles are chemically bound and trapped in a part of the porous chromatographic material (g) to be immobilized. Either method can be used, but in the apparatus of the present invention, direct immobilization is preferred from the viewpoint of uniformity of insolubilization, ease of sensitivity adjustment, and the like.
  • the material (usually a chromatographic material (g)) constituting the detection section (C) is a porous nitrocellulose membrane, a porous cellulose membrane, a nylon membrane, a glass fiber, a nonwoven fabric, a cloth, etc. Those having an active group for binding a substance are preferable, and a porous nitrocellulose membrane and an activated nylon membrane are particularly preferable.
  • the shape of the substance to be detected immobilized on the chromatographic material (g) is not particularly limited, and may be any shape.
  • the chromatographic material that enables uniform detection of the labeled substance with respect to the chromatographic tip. Particular preference is given to a line across (g).
  • the chromatographic material (g) is preferably used after immobilizing the substance for detection and then subjected to a non-specific adsorption preventing treatment such as a treatment with an inert protein.
  • C n) is prepared by immobilizing the hapten antibody on the chromatographic material (g) at different concentrations sequentially from upstream to downstream.
  • the absorption part (D) is a part that absorbs and removes unreacted labeling substances that are not insolubilized in the detection part (C) while the added sample is physically absorbed by the chromatographic transfer.
  • Cellulose filter paper, nonwoven fabric, cloth A water-absorbing material such as cellulose acetate is used. Since the chromatographic speed after the chromatographic tip of the added sample reaches the absorbing part (D) depends on the material and size of the absorbing material, the speed suitable for the measurement of the analyte can be determined by selecting it. Can be set.
  • each part of the device of the present invention has been described above.
  • the chromatographic speed (fluid flow speed) varies depending on factors such as the material, size, and thickness of the part. Therefore, one of these factors should be appropriately selected and set so that qualitative or quantitative analysis can be most suitably performed according to the type of the analyte and the measurement principle.
  • the method and apparatus of the present invention can be applied to qualitative or quantitative (semi-quantitative) analysis by any immunochromatography method. By applying the present invention, clear and reliable analysis results can be obtained in a shorter time than before. Obtainable.
  • Example 1 Application of the present invention in semi-quantitative determination of urinary estrogen (hapten) by immunochromatography
  • estriol one 16- Gurukuronai de was dissolved (hereinafter, E 3 16G hereinafter) (manufactured by Teikoku Seiyaku) 4 Omg dimethyl formamidine de 1. OML, this 4. After adding tri-n-butylamine 20. below C, isobutyl chlorocarbonate 11.21 was added and stirred for 30 minutes. Pre-added serum albumin
  • BSA (Hereinafter referred to as BSA) (manufactured by Biocell) 117 mg dissolved in 2.8 ml of water, 1 NNaOH solution 15 was added, dimethylformamide 2. Oml was added, and the solution was kept at 8 ° C. Was mixed. This was then stirred at 8 ° C, added INNaOH solution 16. 6 l after one hour, further 3. After stirring for 5 hours, Sephadex G-25 in the unreacted E 3 16G and tri -n- Buchiruamin And other low molecular weight reagents were removed. After dialysis (against purified water) and lyophilization, Estrio 1-Ru 16-glucuronide BSA (E16 GBSA) was obtained. The co one bell reactions I a lyophilized powder of antigen binding of BSA1 mole per E 3 16G27 ⁇ 30 mol was confirmed.
  • the 1 was subcutaneously administered to an a) 3 week intervals BALB / C mice (6-8 weeks old) and E 3 16 GB S A25 ⁇ g produced with complete Freund indoor Juba cement, the outermost Later, 50 g was injected intravenously.
  • D'MEM Delpeco's modified minimal basic medium
  • the cells in which activity was observed were diluted in RPMI-1640 medium containing 10% fetal serum containing BALB / C mouse thymocytes and screened by limiting dilution to obtain 10 monoclonal antibody-producing fused cells.
  • I got At least 2 ⁇ 10 6 cells were intraperitoneally administered to BA LB / C mice to which 0.5 ml of pristane had been administered in advance, and ascites tumor was formed to obtain ascites.
  • the ascites was purified by ammonium sulfate fractionation and Afigerupu Rotin A Mabusukitto to give the anti-E 3 16 G monoclonal antibody of white powder and freeze-dried.
  • E 3 16G and Usagi serum albumin (hereinafter in the same manner, using as RSA) (manufactured by Miles Inc.), was prepared E 3 16G- RSA.
  • E 316 G-RSA prepared in 1-c was dissolved in purified water to prepare a 2 mg / ml solution.
  • Colloids gold solution gold colloids particle diameter 10 nm, manufactured by Amersham
  • pH 7. 6 8. to 0 ml by addition of 0. 2MK 2 C0 3 30 ⁇ 1
  • E 3 16G — RSA solution 1001 was added, stirred at room temperature for 10 minutes, added with 40% 0.1% PEG600 solution, stirred for 10 minutes, and centrifuged at 15,000 rpm at 4 ° C for 60 minutes.
  • a filter paper for chromatography (No. 585, 0.85 mm thick, manufactured by Advantech Toyosha Co., Ltd.) was cut to make a 10 x 50 mm filter paper piece, which was then made into 5% skim milk powder (National Dairy Association). Contain 0.1 M Tris buffer (pH 8.2), immerse in a solution, incubate at 37 ° C for 1 hour, wash once with 0.1 M Tris buffer (pH 8.2), then 5% BSA (BioCell ) Contains 0.1M Tris buffer (pH 8.2).
  • Borosilicate glass fiber (Borosilic at eGlass Fiber, average flow hole diameter: 39 j) (LYPORE, Grade 9254, manufactured by Lyda 11 companies) is cut into 10 x 50 mm strips. This is immersed in 0.1 M Tris buffer (pH 8.2) containing 10% nonfat dry milk37. C, after incubation for 90 minutes, washed twice with 0.1 M Tris buffer (pH 8.2), and immersed in 1 M Tris buffer (pH 8.2) containing 5% BSA. After incubation at 37 ° C for 1 hour, put in 0.1 M Tris buffer (pH 8.2) containing 0.1% 83. After soaking, the solution was drained and dried at room temperature, and used as a member for preparing a labeling substance elution promoting member (i) and a labeling substance-containing member (b).
  • the gold colloid-labeled Eal 6G-RSA solution prepared in 1-d) was diluted with the same amount of a 0.1% NaN 3 solution containing 30% sucrose, and the 10 x 20 mm solution obtained in (f-1) above was obtained.
  • the material was impregnated with 1201 and freeze-dried to prepare a labeling substance-containing component (b). This was cut into 5 x 2 mm when the semi-quantitative device was prepared, and used for a 5 x 5 mm labeling substance elution accelerating member (i) sandwiched from above and below by two (11) h) described later.
  • Nitrocellulose membrane (chromate material (g)) (Sartorius, pore size 8 zm) is cut into a size of 30 x 100 mm, and 1-b) using Cammag Linomat IV 0.15, 0.2, 0.3, and 0.4111 / 1111 solutions (50 // 111183 containing 5 OmM Tris buffer, pH 8.2) of the anti-E16G monoclonal antibody prepared in 10 // 1 was sprayed linearly in the order of 12, 14, 16 and 18 mm from one end, left in a thermo-hygrostat at 25 ° C and 80% humidity for 25 minutes, and then 0.1M Tris buffer (pH8) 2) In 5% skim milk powder (National Federation of Dairy Federations) dissolved, then dipped in 5% BSA solution and blocked, then 0.1% Tris buffer containing 1% saccharose and 1% mannitol The cells were washed, allowed to stand at room temperature, and dried to form a detection section (C) containing four detection sites.
  • the nitrocellulose membrane containing the detection section (C) manufactured in 1-g) was cut into 100 mm wide strips of 5 mm width to form a 5 x 3 Omm strip (hereinafter the detection section (C) fixed side with low antibody concentration) Is called upstream).
  • the piece of filter paper for the sample addition section (A) manufactured in 11e) was also cut to make a strip of 8 x 1 Omm.
  • the labeling substance-containing member (b) is overlapped with the chromatographic material (g) so that the upstream end of the chromatographic material (g) overlaps the labeling substance-containing member (b) (5x2 mm) manufactured in 1-f) by lmm. ) And another labeling substance elution accelerating member (i) so as to sandwich the labeling substance-containing member (b).
  • a strip of filter paper (8x10m m) was placed thereon and fixed with the adhesive portion of the double-sided adhesive tape (f) (FIG. 1, d).
  • a piece of 8x15 mm filter paper of chromatography filter paper (Advantech Toyo, No. 585) is used as the absorption part (D), and the downstream part of the strip of the nitrocellulose membrane (chromatographic material (g)) in the detection part (C).
  • the double-sided adhesive tape (f) was fixed to the adhesive surface of the adhesive portion f2 with an overlap of 3 mm from the end.
  • Esutorio Ichiru in the sample compete sequentially from upstream in the movement detection unit to (C) by chromatography move with dissolved gold colloids labeled E 3 16 GR SA by the sample and the downstream fixed anti E 3 16 G monoclonal antibody After the unreacted label moved to the absorption part (D), a colored band was observed at the detection part (C).
  • Table 1 shows the results of this quantitative measurement.
  • column (a) shows the number of colored bands in the detection part (C)
  • column (b) shows the case where band formation was observed (+). The judgment pattern in which the case was not shown is indicated by (1).
  • Table 1 show that semiquantitative results (patterns) were obtained according to the detection sensitivity set for each sample.
  • P-dio13G-BSA was produced in the same manner as in 11a) of Example 1 using pregnanediol-13-glucuronide (hereinafter referred to as P-diol3G) and BSA.
  • Example 1 Using P-dio 13G-BSA produced in 2-a) above, 11-b) of Example 1 In the same manner as described above, four anti-P-dio13G antibody-producing fusion cell lines were obtained.
  • For the monoclonal antibody 2 ⁇ 10 6 cells were transplanted into the abdominal cavity of a BALB / C mouse to which 0.5 ml of pristane had been intraperitoneally administered in advance, and ascites was collected, and the ascites was collected using P-diol 3G-BSA. Purification was performed by affinity chromatography using the bound Sepharose 4B (Pharmacia) to obtain an anti-P-diol 3G monoclonal antibody.
  • P-diol 3G PVMMA Pdi013G-bonded vinyl methyl ether maleic anhydride copolymer
  • Red aminated polystyrene latex solid content: 10%, manufactured by Nippon Synthetic Rubber Co., Ltd., particle size: 0.37 // m
  • 0.5 ml of N, N-dimethylformamide (DMF) 'purified water (1: 1) 12 ml of the prepared 10% triethylamine solution was added and suspended. After stirring for 15 minutes, the mixture was centrifuged.
  • the precipitate was centrifugally washed twice with 10 ml of DMF / water (1: 1) and once with 10 ml of purified water, then suspended in 0.5 ml of purified water, and P-diol prepared in 2-c)
  • To 0.63 ml of 3G PVMMA solution (equivalent to 0.29 mg of pregnanediol), add and mix 1 ml of purified water, and then add 7.5 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride. The reaction was carried out overnight with stirring.
  • the precipitate obtained by centrifugation was repeatedly centrifuged and washed three times with 10 ml of glycine buffer, and then 30% saccharose and 0.1% goat serum albumin (hereinafter referred to as GSA) (Miles Co., Ltd.).
  • GSA goat serum albumin
  • the suspension was suspended in 10 ml of a glycine buffer solution to produce P-diol 3 G PVMMA-bound colored latex.
  • a filter paper for chromatography (No. 526, manufactured by Advantech Toyo Co., Ltd.) was cut into a piece of filter paper of 10 ⁇ 50 mm, and the sample-added part (A) was manufactured in the same manner as in Example 11 e). .
  • Borosilicate glass fiber filter paper Boros ili cat e G 1 a ss Fiber (average pore diameter: 35 m) (L YPORE, GRADE 9818, manufactured by Lydal 1) cut into 10 x 50 mm strips and treated in the same manner as in Example 1-f)
  • a member for producing the labeling substance-containing member (b) and a labeling substance elution promoting member (i) were obtained.
  • the labeled latex-labeled P-dio 13 G PVMMA suspension prepared in 2–d) was cut into a 10 x 20 mm suspension to produce the labeled substance-containing member (b) obtained in (f-11) above. It was impregnated with 120 ⁇ 1 and dried at room temperature. This was cut into 5 x 2 mm when the semi-quantitative device was manufactured to obtain a labeling substance-containing member (b), and a 5 x 5 mm labeling substance elution promoting member (i) was laminated and used in 2-h) described later.
  • Nitrocellulose S-mo (ce 11 u10 set rate on My1ar, pore size 8 / m, manufactured by Zaritrius) is cut into a size of 30 ⁇ 100 mm, and cut with a force mag.
  • 0.5, 1.0, 1.5, and 3 mg / ml solutions (5 OmM Tris buffer containing 50 ⁇ g / ml BSA, pH 8.2) of the anti-P-dial 3G monoclonal antibody prepared in b) 1 was linearly sprayed sequentially at positions 12, 14, 16 and 18 mm from one end, and processed in the same manner as in Example 11-g) to form a detection section (C) having four-stage detection sensitivity.
  • the nitrocellulose membrane (cellulose nitrate on Mylar) used here is a nitrocellulose fiber directly molded on a plastic plate. By using this, distortion due to expansion of the chromatographic material due to wetting by the sample solution can be prevented.
  • Paste (5x5mm), and the downstream end of the labeling substance-containing member (b) (5 x 2mm) manufactured in 2—: f) is the upstream end of the nitrocellulose membrane (chromat (g)) and the labeling substance.
  • a strip of filter paper (8x10mm) was placed on the tape and fixed with the adhesive at the upstream end of the double-sided adhesive tape (f).
  • a nitrocellulose membrane (chromatographic material (g)) containing an 8 x 15 mm filter paper piece from a filter paper for chromatography (Advantic Toyo, No. 585) as the absorbing part (D) and containing the detecting part (C) Double-sided adhesive tape with 3 mm overlap at the downstream end of
  • Pregnanediol in urine was measured in 7 cases of urine from pregnant women. Pregnant women's urine was added at 150/1 to each sample addition section (A) of the semi-quantitative device prepared in 2-h), and the measurement was performed. In this semi-quantitative measurement, the detection sensitivity was 2.5 g / ml or less for four color bands, 5 / g / ml for three bands, 10 /// !! 11 for two bands, and 20 // for one band. It was set to be 40 g / ml or more for 1111 and 0 tubes.
  • Table 3 shows the results.
  • Column (c) shows the semi-quantitative value, and column (d) shows the quantitative value of pregnanediol in the sample by Radioimnoassay (RIA).
  • RIA Radioimnoassay
  • HCG (10000 iu / mg) was administered subcutaneously to the B a1 b / c mouse three times at three-week intervals together with complete Freund's adjuvant, and three weeks later, hCG was intraperitoneally administered.
  • Each cell line was administered intraperitoneally to B a1 b / c mice to which pristane had been administered in advance, and ascites tumor was formed to obtain ascites.
  • the ascites obtained was subjected to ammonium sulfate fractionation and Affigel-Pro Purification was performed using a Tin A Mabs Kit, followed by lyophilization to obtain a white powdered monoclonal antibody.
  • the obtained anti-hCG-specific monoclonal antibody was used for the action of the detection part (C), and the monoclonal antibody recognizing the single subunit was used for producing a labeled antibody.
  • Mouser G (manufactured by Miles) was dissolved in 1 ml of physiological saline, emulsified with the same amount of Complete Freund's adjuvant, and injected subcutaneously into the feet of adult rabbits. This injection was performed three times at one-month intervals. After confirming an increase in antibody titer, whole blood was collected to obtain antiserum. This antiserum was inactivated at 56 ° (30 minutes, then salted with ammonium sulfate, purified by DEAE-cellulose chromatography, and gel-filtered with Sephadex G200 (Pharmacia), and then lyophilized to a white powder. Anti-mouse G antibody was obtained.
  • the anti-hCG monoclonal antibody (antibody recognizing hydsubunit) prepared in 3-a) above was dissolved in Tris buffer (pH 8.2) containing BSA55 / zg / ml, and dissolved in 20 O ⁇ g / A ml solution was prepared.
  • Colloids gold solution gold colloids particle size 10 nm, Amashiamu Co.
  • OML the antibody solution 0. 5 ml
  • 2% 0.1% PEG 6000 solution was added, and after stirring for 10 minutes, 15000 rpm, 4. C, centrifuged for 60 minutes.
  • Example 1 A labeling substance prepared by treating a porous silica glass fiber (average pore diameter: 39 jm) (LYPOREs Grid 9254, manufactured by Lydal 1) with f) and (f-1) Elution promoting member (i) was used.
  • Example 2 Porosilicate glass fiber (average pore diameter: 35 im) (LYPORE, Grade 9818, manufactured by Lydal 1) was manufactured in f) and (f-1). The member was used for producing a marker-containing member (b).
  • Gold colloids labeled anti-hCG monoclonal antibody solution prepared in 3- c) was diluted with 30% Shiyukurosu containing 0. 1% NaN 3 solution the same amount, frozen by 1 20/1 impregnated into the member of 10 x 20 mm After drying, a labeling substance-containing member (b) was prepared. This was cut into 5 x 2 mm when the qualitative apparatus was manufactured, and a 5 x 5 mm labeling substance dissolution promoting member (i) was laminated and used in 3-g) described later.
  • Nitrocellulose membrane (chromate material (g)) (Sartorius, pore size 8 ⁇ m) is cut into a size of 30 x 100 mm, and is then cut using Cammag Linomat IV 3-a) Of a 0.5 mg / m 1 solution (50 mM / g / m IBSA-containing 50 mM Tris buffer, pH 8.2) of the anti-hCG specific monoclonal antibody prepared in Step 1 from one end of the chromatographic material (g) At the position of 10 mm, then use 10% of the 2 mg / ml solution of the anti-mouse G ⁇ sagi antibody prepared in 3-b) (5 OmM Tris buffer containing 50 zg / ml BSA, pH 8.2) as a control.
  • Example 11g After linearly spraying 17 mm from one end of the chromatographic material (g), leave it in a thermo-hygrostat at 25 ° C and 80% humidity for 25 minutes, and then proceed as in Example 11g). After performing blocking treatment and drying, a detection part (C) was prepared.
  • the width of 100 mm of the nitrocellulose membrane including the detection unit (C) manufactured in 3-f) was cut into 5 mm width to form a 5 x 30 mm strip (hereinafter, the anti-hCG antibody fixed side is referred to as upstream).
  • a piece of filter paper for the sample addition section (A) manufactured in 3–d) was also cut to produce an 8 ⁇ 10 mm strip.
  • a double-sided adhesive tape (f) is applied to the entire surface of one side of the plastic plate, which is the support (e).
  • a strip (5 x 30 mm) of a nitrocellulose membrane (chromat (g)) containing (C) was applied (the right end is the upstream end in c) in Fig. 1).
  • the labeling substance-containing member (b) (52 mm) manufactured in 3-e) is placed, and on top of this, the labeling substance elution promoting member manufactured in 3-e) (I) (5x5 mm) was laminated along with the left end of the labeling substance-containing member (b), and the right side was fixed with the adhesive surface of double-sided adhesive tape (:). Further, a strip of filter paper (8 ⁇ 10 mm) for the sample addition section (A) was placed thereon, and fixed with the adhesive section at the upstream end of the double-sided adhesive tape (f). Finally, an 8 ⁇ 15 mm piece of filter paper for filter paper for chromatography (Advantech Toyo, No.
  • 3-g) was prepared with 3-g) except that the labeling substance elution promoting member (i) in the apparatus of the present invention was not used.
  • a device for qualitative analysis similar to that described above was prepared and used as a control.
  • Example 4 Comparison of semi-quantitative performance (clarity and accuracy) depending on the difference in the composition of the labeled substance presence part (B)
  • the configuration of the labeled substance present part (B) of the present invention is the same as that of the Q comparative example (B) shown in a) of FIG. 1 and a) of FIG. (A), b), and c) in Fig. 4 (The configuration in Fig. 4 is one generally used for qualitative immunochromatography such as urinary human placental gonadotropin (hCG). ).
  • the semi-quantitative apparatus of the comparative example uses the same raw materials (materials) as in Example 1 in order to prevent the difference between the raw materials (materials) of the sample addition section (A) and the labeled substance presence section (B).
  • Figure 4 shows a) b) and c).
  • Table 5 shows the time course of the reaction pattern of the samples with estrogen concentrations of 0, 12.5, 25, 50 and 100 ng / ml and the observation results.
  • a sample containing an analyte and a labeling substance for detecting the analyte are synchronized and the chromatographic material is placed on the chromatographic material. It can be moved to get clear and reliable results in a short time.
  • the method or apparatus of the present invention provides a so-called stick-type immunochemical method and apparatus capable of easily, clearly, and semi-quantitatively determining a sample containing the hapten to be analyzed in a short time, in a short time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé de dosage par analyse immunochimique qualitative ou quantitative (semi-quantitative) selon une technique chromatographique qui consiste à dissoudre un marqueur servant d'échelle de référence dans un échantillon contenant le produit à doser, à permettre la migration de l'échantillon et du marqueur vers le site (section de détection) afin d'effectuer une lecture du résultat du dosage et une évaluation visuelle de ce résultat sur la substance chromatographique. En l'occurrence, le procédé simplifié de dosage immunochimique (invention I) consiste à appliquer en couches un produit contenant un marqueur et un produit (accélérateur de l'élution du marqueur) obtenu à partir d'un produit brut au moins aussi grossier que le produit contenant un marqueur. L'invention concerne également un procédé simplifié de dosage immunochimique semi-quantitatif où le produit à doser est un haptène. Ce procédé chromatographique (invention II), qui reprend les éléments indispensables constitutifs de l'invention I, consiste à mettre (1) le produit à doser contenu dans un échantillon et (2) le produit contenant un marqueur utilisé pour le dosage, ou l'une de ses modifications chimiques, en contact avec (3) un anticorps dirigé contre le produit à doser, cet anticorps étant immobilisé sur un seul et même matériau chromatographique sous différentes concentrations indépendantes, d'amont en aval, de façon à provoquer, séquentiellement, d'amont en aval, une suite de réactions compétitives anticorps/antigène, après quoi on détermine la concentration du produit à doser dans l'échantillon en utilisant le marqueur comme échelle de référence. L'invention concerne en outre un dispositif de dosage dont la structure permet de réaliser les inventions I et II. La migration synchrone de l'échantillon et du marqueur sur la substance chromatographique, selon le procédé et le dispositif de la présente invention, aboutit dans des délais très courts à des résultats nets et précis dans un dosage immunochromatographique (dosage qualitatif ou semi-quantitatif). Enfin, l'invention concerne un procédé immuno-chimique et un dispositif semi-quantitatif sous forme de bâtonnets permettant de réaliser un dosage semi-quantitatif commode, net et rapide d'un échantillon contenant un haptène.
PCT/JP1995/001006 1994-05-27 1995-05-25 Procede et dispositif simplifie de dosage immunochimique WO1995033205A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25378/95A AU2537895A (en) 1994-05-27 1995-05-25 Simple method and device for immunochemical assay

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP6/115122 1994-05-27
JP11512294A JP3552272B2 (ja) 1994-05-27 1994-05-27 免疫化学的簡易アッセイ方法および装置
JP6/116913 1994-05-30
JP11691394A JP3519451B2 (ja) 1994-05-30 1994-05-30 イムノクロマト法によるハプテンの半定量方法および装置

Publications (1)

Publication Number Publication Date
WO1995033205A1 true WO1995033205A1 (fr) 1995-12-07

Family

ID=26453707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/001006 WO1995033205A1 (fr) 1994-05-27 1995-05-25 Procede et dispositif simplifie de dosage immunochimique

Country Status (2)

Country Link
AU (1) AU2537895A (fr)
WO (1) WO1995033205A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957319A1 (de) * 1999-11-29 2001-05-31 Febit Ferrarius Biotech Gmbh Dynamische Bestimmung von Analyten
CN107656048A (zh) * 2017-09-15 2018-02-02 刘哲 一种半定量检测抗原或抗体的免疫层析试纸条及其应用
US10712340B2 (en) 2012-01-20 2020-07-14 Ortho-Clinical Diagnostics, Inc. Assay device having controllable sample size

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3479100B2 (ja) * 1993-06-02 2003-12-15 帝国臓器製薬株式会社 免疫化学的簡易半定量方法および装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504166A (ja) * 1989-02-17 1991-09-12 ユニリーバー・ナームローゼ・ベンノートシヤープ 分析検査
JPH04351962A (ja) * 1991-05-29 1992-12-07 Mochida Pharmaceut Co Ltd 特異結合分析方法および特異結合分析装置
JPH055743A (ja) * 1991-01-31 1993-01-14 Wakunaga Pharmaceut Co Ltd 測定装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504166A (ja) * 1989-02-17 1991-09-12 ユニリーバー・ナームローゼ・ベンノートシヤープ 分析検査
JPH055743A (ja) * 1991-01-31 1993-01-14 Wakunaga Pharmaceut Co Ltd 測定装置
JPH04351962A (ja) * 1991-05-29 1992-12-07 Mochida Pharmaceut Co Ltd 特異結合分析方法および特異結合分析装置

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957319A1 (de) * 1999-11-29 2001-05-31 Febit Ferrarius Biotech Gmbh Dynamische Bestimmung von Analyten
US10712340B2 (en) 2012-01-20 2020-07-14 Ortho-Clinical Diagnostics, Inc. Assay device having controllable sample size
CN107656048A (zh) * 2017-09-15 2018-02-02 刘哲 一种半定量检测抗原或抗体的免疫层析试纸条及其应用

Also Published As

Publication number Publication date
AU2537895A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
JP3479100B2 (ja) 免疫化学的簡易半定量方法および装置
US6699722B2 (en) Positive detection lateral-flow apparatus and method for small and large analytes
US4248965A (en) Immunochemical process of measuring physiologically active substances
US7241418B2 (en) Method for immobilizing conjugates in diagnostic tests
EP0516095A2 (fr) Procédé et dispositif d'essai de liaisons spécifiques
EP1082613B1 (fr) Detection d'analytes
JPS6325553A (ja) 金ゾル試薬の調整方法
WO1994019693A1 (fr) Immobilisation de reactifs de dosage par liaison specifique
JP3519451B2 (ja) イムノクロマト法によるハプテンの半定量方法および装置
JP3499570B2 (ja) Ｔｓｈレセプター自己抗体を検出するためのレセプター結合アッセイ
CA2009985A1 (fr) Reactif pour dosage immunologique et dispositif dans lequel il est utilise
CN100384876C (zh) 抗脱唾液酸α1－酸性糖蛋白的单克隆抗体、用于免疫色谱以检测脱唾液酸α1－酸性糖蛋白的诊断条和使用其诊断肝病的方法
US6121056A (en) Random detection of antigens with antibodies immobilized on soluble submicron particles
US5242804A (en) Simultaneous dual analyte assay
JP3552272B2 (ja) 免疫化学的簡易アッセイ方法および装置
WO1995033205A1 (fr) Procede et dispositif simplifie de dosage immunochimique
US5583003A (en) Agglutination assay
US5616503A (en) Determination of haptens
AP156A (en) Agglutination assay.
AU6445090A (en) Agglutination assay

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA